During Friday’s trading session, shares of a global biopharmaceutical company manufacturing biotechnology products and research services are in focus on the stock exchanges, after successfully raising Rs. 4,500 crores via a Qualified Institutions Placement (QIP).
With a market cap of Rs. 41,786.8 crores, at 11:48 a.m., the shares of Biocon Limited were trading in the red at Rs. 348.05 on BSE, down by around 0.2 percent, as against its previous closing price of Rs. 348.6. The stock has delivered positive returns of around 1.3 percent in one year, and has gained by over 4 percent in the last one month.
What’s the News
Biocon Limited has announced that its Fund Raising Committee has approved the issue and allotment of ~13.63 crore equity shares, with a face value of Rs. 5 each, to eligible qualified institutional buyers. These shares were offered at an issue price of Rs. 330 per share, which includes a premium of Rs. 325 apiece. The QIP opened on 16th June 2025 and closed on 19th June 2025.
On 16th June 2025, the company’s Board has given the green light to launch a QIP, aimed at raising up to Rs. 4,500 crores, with the floor price set at Rs. 340.2 per equity share for the issue.
Following the successful allotment of shares, Biocon’s paid-up equity share capital has increased from Rs. 600.3 crore (representing 120 crore equity shares) to nearly Rs. 668.5 crore, now comprising ~133.7 crore equity shares with a face value of Rs. 5 each.
Biocon plans to use the funds raised primarily to reduce a portion of its existing debt. Additionally, a part of the proceeds will be used to buy back the outstanding optionally convertible debentures issued by its subsidiary, Biocon Biologics, to Goldman Sachs and its affiliated investment schemes.
Financials & more
Biocon reported a significant growth in its revenue from operations, showing a year-on-year rise of around 13 percent from Rs. 3,917 crores in Q4 FY24 to Rs. 4,417 crores in Q4 FY25. Similarly, its net profit increased during the same period from Rs. 223 crores to Rs. 459 crores, representing an impressive growth of around 106 percent YoY.
Biocon Limited is engaged in the business of manufacturing biotechnology products and research services. It is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
